GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Cash And Cash Equivalents

New Ray Medicine International Holding (HKSE:06108) Cash And Cash Equivalents : HK$103.95 Mil (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Cash And Cash Equivalents?

New Ray Medicine International Holding's quarterly cash and cash equivalents declined from Dec. 2022 (HK$154.41 Mil) to Jun. 2023 (HK$112.45 Mil) but then stayed the same from Jun. 2023 (HK$112.45 Mil) to Dec. 2023 (HK$103.95 Mil).

New Ray Medicine International Holding's annual cash and cash equivalents increased from Dec. 2021 (HK$150.15 Mil) to Dec. 2022 (HK$154.41 Mil) but then declined from Dec. 2022 (HK$154.41 Mil) to Dec. 2023 (HK$103.95 Mil).


New Ray Medicine International Holding Cash And Cash Equivalents Historical Data

The historical data trend for New Ray Medicine International Holding's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Cash And Cash Equivalents Chart

New Ray Medicine International Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.67 65.76 150.15 154.41 103.95

New Ray Medicine International Holding Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.15 151.89 154.41 112.45 103.95

New Ray Medicine International Holding Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


New Ray Medicine International Holding  (HKSE:06108) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


New Ray Medicine International Holding Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


New Ray Medicine International Holding (HKSE:06108) Business Description

Traded in Other Exchanges
N/A
Address
19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.
Executives
Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping 2201 Interest of corporation controlled by you
Qian Shenglei 2101 Beneficial owner
Zhang Jiang 2201 Interest of corporation controlled by you
Yang Fang 2202 Interest of your spouse
Zhou Ling 2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines